Abstracts tagged "B-Cell Targets"

Abstract Number: 1752 • ACR Convergence 2024
T Cell-Engaging Bispecific Antibodies to Target Autoreactive 9G4 Idiotope B Cells in Systemic Lupus Erythematosus
Jin Liu¹, Yuanxuan Xia¹, Dylan Ferris¹, Elana Shaw¹, Brian Mog¹, Alexander Pearlman¹, Brock Moritz¹, Kyle J. Kaeo¹, Colin Gliech¹, Tolulope Awosika¹, Sarah DiNapoli¹, Tushar Nichakawade¹, Yang Li¹, Jiaxin Ge¹, Stephanie Glavaris¹, Nikita Marcou¹, Taha Ahmedna¹, Regina Bugrovsky², Scott A. Jenks², Chetan Bettegowda¹, Daniel Goldman³, Michelle Petri³, Iñaki Sanz⁴, Kenneth W. Kinzler¹, Shibin Zhou¹, Bert Vogelstein¹, Suman Paul¹, Felipe Andrade⁵ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Emory University School of Medicine, Atlanta, GA, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Emory University School of Medicine, Atlanta, ⁵The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T-cell therapies hold promise for systemic lupus erythematosus (SLE) but are critically limited by scalability and long-term safety (e.g., risk of…
Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Elizabeth Garner, George Kwong, Tristan W Fowler, Heinrich Kufeldt, Brian Kerfs, Julie Kim, Art Aviles, Lynne Alexander, Franco Davi, Chris Holland, Jean-Yves Maziere, Ashraf Garrett, Mara Bryan, Linh Chu, Sarbani Bhaduri, Michele Gerber, Elaine Alambra, Justin Skoble, Tom Kochy, Tonia Nesheiwat, Socorro Portella, Enrique Zudaire and Steven B Kanner, Caribou Biosciences, Berkeley, CA
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…
Abstract Number: 0876 • ACR Convergence 2024
C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases
jiaqi Huang¹, Xin Yao¹, Xiaobing Luo¹, Xiaoteng Lv², Yutian Wei², Michael Patrick¹, Fei Wang², Yi Hong² and Yihong Yao¹, ¹AbelZeta Inc., Rockville, MD, ²AbelZeta Inc., Shanghai, China (People's Republic)
Background/Purpose: B cells are pivotal in autoimmune disease pathogenesis as they produce autoantibodies and undergo aberrant maturation processes, and B-cell dysregulation and the production of…
Abstract Number: 1753 • ACR Convergence 2024
A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases
Georg Schett¹, Emily Littlejohn², Neil Kramer³, Amit Saxena⁴, Philip Mease⁵, Margrit Wiesendanger⁶, Fabian Müller⁷, Ran Reshef⁸, Paolo Caimi⁹, Mohamad Cherry¹⁰, Jingmei Hsu⁴, Krish Patel¹¹, Jacques Azzi⁶, Susana Falcon¹², Thomas Ly¹³, Ken Ogasawara¹², Sharmila Das¹², Jerill Thorpe¹⁴, Michael Maldonado¹², Giuseppina Stifano¹², Ashley Koegel¹² and Anca Askanase¹⁵, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²Cleveland Clinic, Cleveland, OH, ³Atlantic Medical Group, Atlantic Health System, Morristown, NJ, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, ¹⁰Atlantic Health System, Morristown, NJ, ¹¹Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA, ¹²Bristol Myers Squibb, Princeton, NJ, ¹³Bristol Myers Squibb, San Diego, CA, ¹⁴Bristol Myers Squibb, Seattle, WA, ¹⁵Columbia University Medical Center, New York, NY
Background/Purpose: CD19 is an appealing therapeutic target due to its ubiquitous expression on B cells and plasmablasts, which play a key role in the pathogenesis…
Abstract Number: 0019 • ACR Convergence 2024
A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Theresa Hunter¹, Ferran Soldevila¹, Yan Zhang¹, Brittany Ross¹, Daiki Matsuda¹, Yanjie Bao¹, John Li¹, Michelle Nguyen¹, Matthew Butcher¹, MIchael Pica¹, Claudia Fernandez¹, James Vestal¹, Goutam Mondal¹, Yi Kuo¹, Jeffrey Chen¹, Josephine Nguyen², Young Yoon Choi², Diana Galvan¹, Duy Nguyen¹, Donald Jhung², Stuart Sievers¹, Steven Tanis¹, Cory Bentley², Michael Rosenzweig¹, Priya Karmali¹, Adrian Bot¹, Haig Aghajanian¹ and Gregor Adams¹, ¹Capstan Therapeutics, San Diego, CA, ²Capstan Therapeutics, San Diego
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating clinical efficacy in various autoimmune disease indications. Despite…
Abstract Number: 1130 • ACR Convergence 2024
Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease
Melanie Hagen¹, Laura Bucci¹, Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: B-cells and plasma cells are key drivers of systemic autoimmune diseases (AID). Recent data demonstrated preliminary safety and efficacy of using the CD3xCD19 bispecific…
Abstract Number: 1801 • ACR Convergence 2024
Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
Tania Rowley¹, Adnan R. Khan¹, Laura McLaughlin¹, Hannah Cherry¹, Farnaz Fallah-Arani¹, Yiannis Ioannou¹, Debasish Pyne² and Anthony Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom
Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
Abstract Number: 0086 • ACR Convergence 2024
Evaluating the Efficacyof B Cell Targeting Drug Candidates Using a Humanized BAFF Transgenic SLE Mouse Model
Juan Liang, Shuxin Xu, Qiuping Xu and Yuxi Zhang, GemPharmatech, San Diego
Background/Purpose: B-cell-activating factor (BAFF) plays a critical role in B cell survival, and its elevated expression can contribute to the presence of autoreactive B cells,…
Abstract Number: 1162 • ACR Convergence 2024
Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom
Xia Lyu¹, Patrick Gordon², Harsha Gunawardena³, Neil McHugh⁴, Sarah Tansley⁴, Athiveeraramapandian Prabu⁵, Peter Lanyon⁶, James Miller⁷, Voon Ong⁸, Anthony Isaacs⁹, Chee-Seng Yee¹⁰, Caroline Cotton¹¹, Patrick Kiely¹², Eleni Stathopoulou¹³, James Taylor¹⁴, Rachel Jeffery¹⁴, Anurag Bharadwaj¹⁵, James Lilleker¹⁶, Janine Lamb¹⁷ and hector Chinoy¹⁸, and MYOPROSP consortium, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ²nhs, London, United Kingdom, ³North Bristol NHS Trust, and Academic Rheumatology, University of Bristol, Bath, United Kingdom, ⁴University of Bath, Bath, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁶Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom, ⁷Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁸University College London, London, England, United Kingdom, ⁹Department of Rheumatology, London North West University Healthcare NHS Trust, London, United Kingdom, ¹⁰Department of Rheumatology, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ¹¹Department of Rheumatology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom, ¹²Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, United Kingdom, ¹³Department of Rheumatology, Solihull Hospital, University Hospitals of Birmingham NHS FT, Birmingham, United Kingdom, ¹⁴Department of Rheumatology, Northampton General Hospital, Northampton General Hospital NHS Trust, Northampton, United Kingdom, ¹⁵1Basildon University Hospital, Mid & South Essex NHS Foundation Trust, Rheumatology, Basildon, United Kingdom, Basildon, United Kingdom, ¹⁶Northern Care Alliance NHS Trust, Salford, United Kingdom, ¹⁷University of Manchester, UK, Manchester, United Kingdom, ¹⁸The University of Manchester, Manchester, United Kingdom
Background/Purpose: B cell depletion in the form of rituximab (RTX) is an established treatment modality for idiopathic inflammatory myopathies (IIM). Treatment response is now assessed…
Abstract Number: 1841 • ACR Convergence 2024
Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
Kristen Zhang, Joanne Li, Duy Nguyen, Nguyen Tan, Hsin-Yuan Cheng, David Huang, Suhasni Gopalakrishnan, Zachary Roberts, Cesar Sommer and Elvin Lauron, Allogene Therapeutics, South San Francisco, CA
Background/Purpose: Autologous CD19 chimeric antigen receptor (CAR) T cell therapies have recently shown to be well tolerated and highly effective in patients with autoimmune diseases…
Abstract Number: 0129 • ACR Convergence 2024
The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, a Prospective 24- Week Study
Qiang Shu¹, Qing Zuraw², Xiaoyu Zhang³, Guillermo Pons-Estel⁴, Shuning Sun⁵, Qincheng Che¹, Xinyu Li⁶, Jie Li⁶ and Qi Liu⁶, ¹Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Rheumatology, Jinan, China, Jinan, China (People's Republic), ²RemeGen Biosciences, Inc., South San Francisco, China (People's Republic), ³Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan China, Beijing, China, ⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ⁵Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Pheumatology, Jinan, China, Jinan, China (People's Republic), ⁶Qilu Hospital, Jinan, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a challenging disease to treat and lack effective therapies. Rituximab (RTX) can deplete CD20+ peripheral B cells. Telitacicept (TA) is…
Abstract Number: 1276 • ACR Convergence 2024
Therapeutic Drug Monitoring (TDM) of Rituximab to Predict Early B-Cell Repopulation in Children
Rana Alsulami¹, Bindiya Chugani², Joley Johnstone², Ann Yeh², Floris Loeff³, Linda Hiraki², Andrea Knight⁴, Deborah Levy² and Ruud Verstegen², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Rituximab is increasingly used in pediatric inflammatory diseases, with dosing extrapolated from adult data due to a lack of pediatric-specific pharmacokinetic (PK) information. Children…
Abstract Number: 1858 • ACR Convergence 2024
Co-modification of Citrullinated Proteins with Malondialdehyde-Acetaldehyde Leads to Amplified T Cell Responses and Increased Disease-specific Autoantibody Concentrations
Breanna Butler¹, Wenxian Zhou², Michael Duryee¹, Nozima Aripova¹, Engle Sharp¹, Carlos Hunter¹, Bridget Kramer¹, Harlan Sayles¹, James O'Dell¹, Geoffrey Thiele¹, Bryant England¹, Joshua Baker³, Andreas Reimold⁴, Gail Kerr⁵ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴Dallas VA Medical Center, Dallas, TX, ⁵Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is highly specific to rheumatoid arthritis (RA). Beyond citrullination, other post-translational protein modifications including malondialdehyde-acetaldehyde (MAA) are targeted by T…
Abstract Number: 0244 • ACR Convergence 2024
Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series
Pei-Hsinq Lai¹, Cheng-Hsun Lu² and Song-Chou Hsieh³, ¹Taipei City Hospital, Taipei, Taiwan (Republic of China), ²National Taiwan University Hospital, Taipei, Taiwan, ³National Taiwan University Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: Post-COVID interstitial lung disease (post-COVID ILD) is a critical sequelae yet the role of immunomodulatory therapies remains unclear. We explored to characterize post-COVID ILD…
Abstract Number: 1396 • ACR Convergence 2024
Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis
Samuel Bitoun¹, Bineta Ly², Audrey Paoletti², Catherine Menier Menier³, Marc Pallardy⁴, Bernard Maillere⁵ and Xavier Mariette⁶, and ABIRISK consortium, ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Rheumatology departement, Université Paris Saclay, Inserm UMR 1184,Hopital Bicêtre, APHP, FHU CARE, Le Kremlin Bicêtre, France, ³1 CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, ⁴Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, France, ⁵CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Rituximab (RTX) provides long lasting efficacy in the control of rheumatoid arthritis. Among factors associated with RTX failure are the occurrence of anti-drug antibodies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].